Ariadne Participates in Muscular Dystrophy Biomarker Project | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariadne said today it is collaborating with European consortium BIO-NMD on a project to identify biomarkers for Duchenne and Becker muscular dystrophies and collagen VI myopathies.

Ariadne will provide bioinformatics tools for identifying functional pathways, potential targets, and data outflow integration, the company said in a statement. Its software suit, Pathway Studio, will be the core product used for integrating data and information flow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.